These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23199508)

  • 61. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
    Vazquez C; Tan CY; Horner SM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31534039
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Advances in hepatitis C: what is coming in the next 5 years?
    Locarnini SA; Bartholomeusz A
    J Gastroenterol Hepatol; 2002 Apr; 17(4):442-7. PubMed ID: 11982725
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors.
    Hwang JY; Kim HY; Park DS; Choi J; Baek SM; Kim K; Kim S; Seong S; Choi I; Lee HG; Windisch MP; Lee J
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6467-73. PubMed ID: 24125883
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Molecular mechanisms of hepatitis C virus (HCV) replication - implications for the development of antiviral drugs].
    Bühler S; Bartenschlager R
    Z Gastroenterol; 2011 Jul; 49(7):836-44. PubMed ID: 21766263
    [TBL] [Abstract][Full Text] [Related]  

  • 66. HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.
    Calle Serrano B; Manns MP
    Antivir Ther; 2012; 17(6 Pt B):1133-46. PubMed ID: 23188760
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibition of hepatitis C virus infection by polyoxometalates.
    Qi Y; Xiang Y; Wang J; Qi Y; Li J; Niu J; Zhong J
    Antiviral Res; 2013 Nov; 100(2):392-8. PubMed ID: 24025401
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An overview of emerging therapies for the treatment of chronic hepatitis C.
    Ilyas JA; Vierling JM
    Med Clin North Am; 2014 Jan; 98(1):17-38. PubMed ID: 24266912
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.
    Beard MR; Ffrench R; Gowans EJ; Helbig KJ; Eyre NM; Douglas MM; Grebely J; Ahlenstiel G; Locarnini S; George J; Shackel NA; White PA; Thompson AJ; Drummer HE
    Gastroenterology; 2014 Jul; 147(1):e1-4. PubMed ID: 24861641
    [No Abstract]   [Full Text] [Related]  

  • 70. Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation.
    Colpitts CC; Chung RT; Baumert TF
    ACS Infect Dis; 2017 Sep; 3(9):620-623. PubMed ID: 28812869
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents].
    Watashi K; Shimotohno K
    Uirusu; 2005 Jun; 55(1):105-10. PubMed ID: 16308536
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting host factors: a novel rationale for the management of hepatitis C virus.
    Khattab MA
    World J Gastroenterol; 2009 Jul; 15(28):3472-9. PubMed ID: 19630100
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection.
    Gastaminza P; Whitten-Bauer C; Chisari FV
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):291-6. PubMed ID: 19995961
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment as prevention and cure towards global eradication of hepatitis C virus.
    Hagan LM; Wolpe PR; Schinazi RF
    Trends Microbiol; 2013 Dec; 21(12):625-33. PubMed ID: 24238778
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vitro methods for testing antiviral drugs.
    Rumlová M; Ruml T
    Biotechnol Adv; 2018; 36(3):557-576. PubMed ID: 29292156
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cyclophilins as modulators of viral replication.
    Frausto SD; Lee E; Tang H
    Viruses; 2013 Jul; 5(7):1684-701. PubMed ID: 23852270
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hepatitis C virus entry: possible targets for therapy.
    Timpe JM; McKeating JA
    Gut; 2008 Dec; 57(12):1728-37. PubMed ID: 19022929
    [No Abstract]   [Full Text] [Related]  

  • 78. Locking out viral replication.
    Begley DW; Varani G
    Nat Chem Biol; 2009 Nov; 5(11):782-3. PubMed ID: 19841624
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Research technique: the murine candidate.
    Dolgin E
    Nature; 2011 Jun; 474(7350):S14-5. PubMed ID: 21666729
    [No Abstract]   [Full Text] [Related]  

  • 80. Deal watch: GSK invests in targeting microRNA for the treatment of hepatitis C.
    Nat Rev Drug Discov; 2010 May; 9(5):350. PubMed ID: 20431557
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.